 | Up a level |
Journal Article
Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., Hoechstetter, M., Fink, A., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C., Eichhorst, B., Hallek, M. and Goede, V. (2017). CHARACTERISTICS, TREATMENT, AND OUTCOMES OF >= 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Haematologica, 102. S. 421 - 422. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., M., Hochstaetter, Fink, A. M., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C. M., Eichhorst, B., Hallek, M. and Goede, V. (2017). Characteristics, treatment, and outcomes of >= 80 year old patients with chronic lymphocytic leukemia (CLL) enrolled to prospective trials of the German CLL study group. Oncol. Res. Treat., 40. S. 139 - 140. BASEL: KARGER. ISSN 2296-5262
Al-Sawaf, O., Kluth, S., Bahlo, J., Hopfinger, G., Fink, A. M., Cramer, P., Maurer, C., Bergmann, M., Dreyling, M., Lange, E., Kneba, M., Stilgenbauer, S., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 39. S. 212 - 214. BASEL: KARGER. ISSN 2296-5262
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., Langerbeins, P., von Tresckow, J., Maurer, C., Kutsch, N., Lange, E., Kiehl, M., Fischer, K., Stilgenbauer, S., Wendtner, C-M, Goede, V, Hallek, M. and Eichhorst, B. (2018). Incidence and outcome of Richter transformation in chronic lymphocytic leukaemia (CLL) - A meta-analysis of German CLL Study Group (GCLLSG) trials. Oncol. Res. Treat., 41. S. 166 - 167. BASEL: KARGER. ISSN 2296-5262
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., Von Tresckow, J., Lange, E., Kiehl, M., Dreyling, M., Ritgen, M., Duerig, J., Tausch, E., Schneider, C., Stilgenbauer, S., Wendtner, C. M., Fischer, K., Goede, V, Hallek, M. and Eichhorst, B. . Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Bergmann, M., Seiler, T., Lange, E., Kneba, M., Stilgenbauer, S., Doehner, H., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B. and Hopfinger, G. (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 31 (10). S. 2251 - 2255. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., von Tresckow, J., Cramer, P., Langerbeins, P., Kutsch, N., Wendtner, C. M., Fischer, K., Eichhorst, B., Goede, V. and Hallek, M. (2017). Mode of progression correlates with further clinical outcome of chronic lymphocytic leukemia (CLL). A meta-analysis by the German CLL study group. Oncol. Res. Treat., 40. S. 138 - 139. BASEL: KARGER. ISSN 2296-5262
Bahlo, J., Goede, V, Kutsch, N., Fischer, K., Fink, A. -M, Stilgenbauer, S., Bergmann, M., Eichhorst, B. and Hallek, M. (2016). Evaluation of the international prognostic index for chronic lymphocytic leukemia (CLL-IPI) in elderly patients with comorbidities: Analysis of the CLL11 study population. Oncol. Res. Treat., 39. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262
Bahlo, J., Kutsch, N., Bergmann, M., Byrd, J., Doehner, H., Eichhorst, B., Else, M., Geisler, C., Grever, M., Lepretre, S., Neuberg, D., Oscier, D., Robak, T., Rosenquist, R., Shanafelt, T., Stilgenbauer, S. and Hallek, M. (2015). THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS. Haematologica, 100. S. 313 - 315. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Cramer, P., von Tresckow, J., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M., Wesselmann, J. S., Annolleck, T., Pflug, N., Kovacs, G., Fischer, K., Wendtner, C-M, Kreuzer, K. -A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2015). CLL2-BIG, -BAG, -BCG and -BIO: A series of four phase-II trials evaluating a sequential regimen of combined targeted therapy aiming for a total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 38. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Seiler, T., von Weikersthal, L. Fischer, Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). Haematologica, 102. S. 171 - 173. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Tausch, E., Seiler, T., von Weikersthal, Fischer L., Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 40. S. 24 - 25. BASEL: KARGER. ISSN 2296-5262
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Fuerstenau, M., Engelke, A., Fink, A. -M, Fischer, K., Kreuzer, K. -A, Ritgen, M., Boettcher, S., Wendtner, C. -M, Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2018). Comparison of 3 different phase II studies using sequential combinations of targeted agents to treat chronic lymphocytic leukemia. Oncol. Res. Treat., 41. S. 29 - 31. BASEL: KARGER. ISSN 2296-5262
Edelmann, J., Tausch, E., Landau, D. A., Robrecht, S., Bahlo, J., Fischer, K., Fink, A. M., Bloehdorn, J., Holzmann, K., Boettcher, S., Werner, L., Kneba, M., Gribben, J. G., Neuberg, D. S., Wu, C. J., Hallek, M., Doehner, H. and Stilgenbauer, S. (2017). Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia, 31 (3). S. 734 - 740. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Elter, T., James, R., Busch, R., Winkler, D., Ritgen, M., Boettcher, S., Kahl, C., Gassmann, W., Stauch, M., Hasan, I., Staib, P., Fischer, K., Fink, A-M, Bahlo, J., Buehler, A., Doehner, H., Wendtner, C-M, Stilgenbauer, S., Engert, A. and Hallek, M. (2012). Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia, 26 (12). S. 2549 - 2554. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924
Fink, A. M., Maurer, C., Bahlo, J., Kluth, S., Linde, H., Aldaoud, A., Illmer, T., Dengler, J., Klausmann, M., Lathan, B., Al-Sawaf, O., Fischer, K., Wendtner, C. -M, Eichhorst, B. and Hallek, M. (2016). Three years after the start of enrolment: Current data from the prospective CLL-registry of the German CLL Study Group. Oncol. Res. Treat., 39. S. 256 - 257. BASEL: KARGER. ISSN 2296-5262
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A. -M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Du, K. Le, Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., Wendtner, C. -M., Langerak, A. W., Kreuzer, K. -A., Ritgen, M., Goede, V., Stilgenbauer, S., Mobasher, M. and Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 380 (23). S. 2225 - 2237. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
Fischer, K., Bahlo, J., Fink, A. -M., Busch, R., Boettcher, S., Kreuzer, K. -A., Maurer, C., Mayer, J., Dreger, P., Kneba, M., Doehner, H., Wendtner, C. -M., Stilgenbauer, S., Hallek, M. and Eichhorst, B. (2014). Long Term Remissions After FCR Chemoimmunotherapy In Patients With CLL. Oncol. Res. Treat., 37. S. 86 - 87. BASEL: KARGER. ISSN 2296-5262
Fuerstenau, M., Bahlo, J., Fink, A. M., Lange, E., Dreger, P., Dreyling, M., Hess, G., Ritgen, M., Kneba, M., Doehner, H., Stilgenbauer, S., Wendtner, C. M., Goede, V., Fischer, K., Boettcher, S., Hallek, M. and Eichhorst, B. (2020). Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia, 34 (3). S. 924 - 929. LONDON: SPRINGERNATURE. ISSN 1476-5551
Goede, V., Bahlo, J., Robrecht, S., Al-Sawaf, O., Fink, A. -M., Wendtner, C. -M., Stilgenbauer, S., Fischer, K., Eichhorst, B. and Hallek, M. (2017). CUMULATIVE ILLNESS RATING SCALE PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA: AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG. Haematologica, 102. S. 72 - 73. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Bahlo, J., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). A new prognostic model based on clinical, biological and genetic parameters improves prognostication in early stage CLL patients: results of the prospective CLL1 trial of the German CLL study group. Oncol. Res. Treat., 40. S. 25 - 27. BASEL: KARGER. ISSN 2296-5262
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Bahlo, J., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia, 31 (12). S. 2833 - 2838. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Klymenko, T., Bloehdorn, J., Bahlo, J., Robrecht, S., Akylzhanova, G., Cox, K., Estenfelder, S., Wang, J., Edelmann, J., Strefford, J. C., Wojdacz, T. K., Fischer, K., Hallek, M., Stilgenbauer, S., Cragg, M., Gribben, J. and Braun, A. (2018). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia, 32 (2). S. 364 - 376. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Klymenko, T., Bloehdorn, J., Bahlo, J., Robrecht, S., Wang, J., Fischer, K., Akylzhanova, G., Edelmann, J., Estenfelder, S., Strefford, J., Wojdacz, T., Hallek, M., Stilgenbauer, S., Cragg, M., Gribben, J. and Braun, A. (2017). NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES. Haematologica, 102. S. 228 - 229. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Knittel, G., Korovkina, D., Liedgens, P., Fritz, C., Al-Baldawi, Y., Bahlo, J., Herling, C., Eichhorst, B., Hallek, M., Persigehl, T., Buettner, R. and Reinhardt, H. C. (2016). ESTABLISHMENT OF A PRE-CLINICAL IN VIVO PLATFORM SPANNING LOW-RISK TO HIGH-RISK CLL. Haematologica, 101. S. 9 - 11. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Knittel, G., Korovkina, D., Liedgens, P., Rehkaemper, T., Fritz, C., Torgovnick, A., Al-Baldawi, Y., Al-Maarri, M., Cun, Y., Fedorchenko, O., Riabinska, A., Beleggia, F., Nguyen, P. -H., Wunderlich, F. T., Ortmann, M., Montesinos-Rongen, M., Tausch, E., Stilgenbauer, S., Frenzel, L., Herling, M., Herling, C., Bahlo, J., Hallek, M., Peifer, M., Buettner, R., Persigehl, T. and Reinhardt, H. C. (2017). Novel models of high-risk CLL reveal an actionable PARP1 dependence in ATM-defective CLL in vivo. Oncol. Res. Treat., 40. S. 27 - 28. BASEL: KARGER. ISSN 2296-5262
Kovacs, G., Bahlo, J., Kluth, S., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Langerbeins, P., Gross-Opphoff-Mueller, C., Fischer, K., Wendtner, C. -M., Kreuzer, K. -A., Stilgenbauer, S., Hallek, M., Eichhorst, B. and Goede, V. (2015). Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 38. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Kron, F., Nadine, K., Kostenko, A., Dohle, I, Mueller, D., Bahlo, J., Bergwelt, M., Eichhorst, B., Hallek, M. and Zander, T. (2016). Profit center analysis of chronic lymphatic leukemia cases: a hospital management perspective. Oncol. Res. Treat., 39. S. 258 - 259. BASEL: KARGER. ISSN 2296-5262
Kutsch, N., Goede, V, Robrecht, S., Kelma, F., Bahlo, J., Fischer, K., Fink, A. -M, Schlag, R., Lange, E., Weide, R., Dreyling, M., Jaeger, U., Stilgenbauer, S., Doehner, H., Kneba, M., Ritgen, M., Wendtner, C. -M, Hallek, M. and Eichhorst, B. (2018). Treatment response and health-related quality of life during management of chronic lymphocytic leukemia (CLL) - a metaanalysis of 3 phase III studies of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 41. S. 30 - 31. BASEL: KARGER. ISSN 2296-5262
Loeschcke, K., Fink, A., Bahlo, J., Westermann, A., Zey, A., Fischer, K., Wendtner, C. M., Noesslinger, T., Ghia, P., Bosch, F., Kater, A. P., Kreuzer, K. A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). CENTRAL SCREENING ENABLES IDENTIFICATION OF HIGH RISK CLL PATIETNS FOR LENALIDOMIDE MAINTENANCE THERAPY WITHIN THE CLLM1 TRIAL OF THE GERMAN CLL STUDY GROUP. Haematologica, 99. S. 587 - 589. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Maurer, C., Fink, A. M., Robrecht, S., Bahlo, J., Fischer, K., Eichhorst, B. and Hallek, M. (2018). First-line treatment and outcome in patients with chronic lymphocytic leukemia (CLL) according to age: a report of the German CLL Study Group (GCLLSG) registry. Oncol. Res. Treat., 41. S. 170 - 172. BASEL: KARGER. ISSN 2296-5262
Maurer, C., Langerbeins, P., Bahlo, J., Cramer, P., Fink, A. M., Pflug, N., Engelke, A., von Tresckow, J., Kovacs, G., Stilgenbauer, S., Wendtner, C-M, Mueller, L., Ritgen, M., Seiler, T., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. Leukemia, 30 (10). S. 2019 - 2026. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Pflug, N., Kluth, S., Vehreschild, J. J., Bahlo, J., Tacke, D., Biehl, L., Eichhorst, B., Fischer, K., Cramer, P., Fink, A. -M, von Bergwelt-Baildon, M., Hallek, M., Cornely, O. A. and Vehreschild, M. J. G. T. (2015). Impact of antibiotic treatment modulating the intestinal microbiota on the efficacy of antineoplastic treatment for chronic lymphatic leukaemia or relapsed lymphoma. Oncol. Res. Treat., 38. S. 175 - 176. BASEL: KARGER. ISSN 2296-5262
Pflug, N., Maurer, C., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Gross-Ophoff, C., Langerbeins, P., Fink, A. -M., Eichhorst, B., Kreuzer, K. -A., Tausch, E., Stilgenbauer, S., Boettcher, S., Doehner, H., Kneba, M., Hallek, M., Wendtner, C. -M., Bergmann, M. and Fischer, K. (2015). Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG). Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M. and van Dongen, J. (2016). QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY. Haematologica, 101. S. 149 - 151. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Tausch, E., Landau, D., Taylor-Weiner, A., Stewart, C., Reiter, J., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Boettcher, S., Cibulskis, K., Mertens, D., Sougnez, C., Rosenberg, M., Hess, J., Carter, S., Edelmann, J., Kless, S., Fink, A., Fischer, K., Ritgen, M., Kneba, M., Gabriel, S., Lander, E., Nowak, M., Doehner, H., Hallek, M., Neuberg, D., Getz, G., Stilgenbauer, S. and Wu, C. (2015). WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS. Haematologica, 100. S. 335 - 337. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Tiao, G., Improgo, M. R., Kasar, S., Poh, W., Kamburov, A., Landau, D-A, Tausch, E., Taylor-Weiner, A., Cibulskis, C., Bahl, S., Fernandes, S. M., Hoang, K., Rheinbay, E., Kim, H. T., Bahlo, J., Robrecht, S., Fischer, K., Hallek, M., Gabriel, S., Lander, E. S., Stilgenbauer, S., Wu, C. J., Kiezun, A., Getz, G. and Brown, J. R. (2017). Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia, 31 (10). S. 2244 - 2248. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Tiao, G., Improgo, M. R., Kasar, S., Poh, W., Kamburov, A., Landau, D. -A., Tausch, E., Taylor-Weiner, A., Cibulskis, C., Bahl, S., Fernandes, S. M., Hoang, K., Rheinbay, E., Kim, H. T., Bahlo, J., Robrecht, S., Fischer, K., Hallek, M., Gabriel, S., Lander, E., Stilgenbauer, S., Wu, C., Kiezun, A., Getz, G. and Brown, J. (2017). GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica, 102. S. 65 - 66. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M, Klaproth, H., Tausch, E., Fischer, K., Wendtner, C-M, Kreuzer, K. -A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262
von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M., Klaproth, H., Tausch, E., Fischer, K., Wendtner, C. -M., Kreuzer, K. -A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. Oncol. Res. Treat., 39. S. 117 - 119. BASEL: KARGER. ISSN 2296-5262